Long noncoding RNA profiling for prognostication in adult acute myeloid leukaemia: abridged secondary publication
HW Ip1,2; WF Tang1; AYH Leung3; H Sun4; JCC So5; JWH Wong6
1 Department of Pathology, Queen Mary Hospital
2 Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong
3 Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong
4 Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong
5 Department of Pathology, Hong Kong Children’s Hospital
6 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong
1. Whole transcriptome sequencing identified
a 10-gene long noncoding RNA (lncRNA)
prognostic score that has prognostic effects
independent of standard European LeukemiaNet
risk stratification in acute myeloid leukaemia
(AML).
2. The lncRNA prognostic score facilitated more accurate risk stratification in favourable-risk and intermediate-risk AML patients.
3. External validity of the lncRNA prognostic score was demonstrated using large external datasets from Beat-AML and TCGA-LAML.
4. A clinical-grade capture-seq assay was devised and validated to facilitate cost-effective implementation of the lncRNA prognostic score in clinical laboratories.
2. The lncRNA prognostic score facilitated more accurate risk stratification in favourable-risk and intermediate-risk AML patients.
3. External validity of the lncRNA prognostic score was demonstrated using large external datasets from Beat-AML and TCGA-LAML.
4. A clinical-grade capture-seq assay was devised and validated to facilitate cost-effective implementation of the lncRNA prognostic score in clinical laboratories.